Stockreport

What CG Oncology (CGON)'s FDA BLA Submission and Phase 3 Progress Mean for Shareholders [Yahoo! Finance]

CG Oncology, Inc. - Common stock  (CGON) 
PDF FDA for cretostimogene, its therapy targeting high-risk BCG-unresponsive non-muscle invasive bladder cancer, along with early completion of enrollment in the Phase 3 PIV [Read more]